369 related articles for article (PubMed ID: 29930278)
1. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
2. Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor.
Tsugawa T; Shinohara R; Nagasaka A; Nakano I; Takeda F; Nagata M; Oda N; Sawai Y; Hayakawa N; Suzuki A; Itoh M
J Endocrinol; 2004 Jun; 181(3):429-35. PubMed ID: 15171691
[TBL] [Abstract][Full Text] [Related]
3. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
4. Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophils.
Suzuki K; Kawamura T; Sakakibara F; Sasaki H; Sano T; Sakamoto N; Hotta N
Diabet Med; 1999 Jan; 16(1):67-73. PubMed ID: 10229296
[TBL] [Abstract][Full Text] [Related]
5. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
6. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y
Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
[TBL] [Abstract][Full Text] [Related]
7. Polyol pathway in tissues of spontaneously diabetic Chinese hamsters (Cricetulus griseus) and the effect of an aldose reductase inhibitor, ONO-2235.
Sekiguchi M; Watanabe K; Eto M; Iwashima Y; Morikawa A; Takahashi M; Ishii K; Makino I
Comp Biochem Physiol B; 1991; 98(4):637-40. PubMed ID: 1907900
[TBL] [Abstract][Full Text] [Related]
8. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Iso K; Tada H; Kuboki K; Inokuchi T
J Diabetes Complications; 2001; 15(5):241-4. PubMed ID: 11522497
[TBL] [Abstract][Full Text] [Related]
10. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Isogai S; Inokuchi T; Ohe K
Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
[TBL] [Abstract][Full Text] [Related]
11. Effects of high glucose concentrations and epalrestat on sorbitol and myo-inositol metabolism in cultured rabbit aortic smooth muscle cells.
Sakakibara F; Hotta N; Koh N; Sakamoto N
Diabetes; 1993 Nov; 42(11):1594-600. PubMed ID: 8405700
[TBL] [Abstract][Full Text] [Related]
12. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
13. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
Steele JW; Faulds D; Goa KL
Drugs Aging; 1993; 3(6):532-55. PubMed ID: 8312678
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
15. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
16. Polyol pathway and protein kinase C activity of rat Schwannoma cells.
Kamiya H; Nakamura J; Hamada Y; Nakashima E; Naruse K; Kato K; Yasuda Y; Hotta N
Diabetes Metab Res Rev; 2003; 19(2):131-9. PubMed ID: 12673781
[TBL] [Abstract][Full Text] [Related]
17. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ligezka AN; Radenkovic S; Saraswat M; Garapati K; Ranatunga W; Krzysciak W; Yanaihara H; Preston G; Brucker W; McGovern RM; Reid JM; Cassiman D; Muthusamy K; Johnsen C; Mercimek-Andrews S; Larson A; Lam C; Edmondson AC; Ghesquière B; Witters P; Raymond K; Oglesbee D; Pandey A; Perlstein EO; Kozicz T; Morava E
Ann Neurol; 2021 Dec; 90(6):887-900. PubMed ID: 34652821
[TBL] [Abstract][Full Text] [Related]
18. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients.
Hamada Y; Odagaki Y; Sakakibara F; Naruse K; Koh N; Hotta N
Life Sci; 1995; 57(1):23-9. PubMed ID: 7596218
[TBL] [Abstract][Full Text] [Related]
19. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
20. Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency.
Ii S; Ohta M; Kudo E; Yamaoka T; Tachikawa T; Moritani M; Itakura M; Yoshimoto K
Diabetologia; 2004 Mar; 47(3):541-548. PubMed ID: 14968292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
